Improvement in symptoms after H₂-receptor antagonist-based therapy for eradication ofH pyloriinfection

Abstract

The triple therapy including lafutidine is equivalent to triple therapy including lansoprazole in terms of H pylori eradication rates and improvement in gastroesophageal reflux and abdominal symptoms. These results are attributed to the fact that lafutidine has strong, continuous antisecretory activity, unaffected by CYP2C19 polymorphisms.

Lafutidine versus Lansoprazole in Combination with Clarithromycin and Amoxicillin for One versus Two Weeks for Helicobacter pylori Eradication in Korea

“…Both the LFT and the lansoprazole treatment regimens were very effective for the improvement of symptoms such as epigastric pain and gastroesophageal reflux, consistent with the findings of the Japanese study [21]. However, the LFT regimen had a greater effect on the relief of heartburn compared to the lansoprazole regimen.…”

Comparison of Lafutidine and Rabeprazole in 7‐day Second‐line Amoxicillin‐ and Metronidazole‐Containing Triple Therapy for Helicobacter pylori: A Pilot Study

“…Most studies on H. pylori eradication using triple therapy have therefore used PPIs as antisecretory drugs. A recent study showed that triple therapy including an H2‐receptor antagonist is equivalent to triple therapy including a PPI in terms of H. pylori eradication rates and improvement in gastroesophageal reflux and abdominal symptoms [9]. Several studies have shown good results with regimens including H2‐receptor antagonists instead of PPIs [20,21], but controlled studies comparing H2‐receptor antagonist‐based triple therapy with PPI‐based triple therapy are scant.…”

“…Hagiwara et al. [9] also compared similar triple therapies including either lafutidine or lansoprazole, and the eradication rates were 66.7% by ITT analysis and 70.0% by PP analysis in the lafutidine group and 72.7% by ITT analysis and 70.0% by PP analysis in the lansoprazole group. Kim et al.…”

“…Lafutidine is a newly developed H2‐receptor antagonist that continuously suppresses gastric acid secretion and protects the gastric mucosa by gastroprotective action through capsaicin‐sensitive afferent neurons, and it is relatively inexpensive compared to a PPI [8]. It has been reported to be more potent and to have longer lasting H2‐receptor blocking activity than famotidine or cimetidine [9]. After oral administration, lafutidine induced a more rapid rise in intragastric pH than did rabeprazole at 20 mg in fasting and postprandial H. pylori ‐negative male patients.…”

An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition

“…Lafutidine promptly suppresses gastric acid secretion, hence it is considered to be a useful drug for the on-demand treatment of mild gastroesophageal reflux disease [16] . Studies have shown that a triple therapy with lafutidine, clarithromycin and amoxicillin shows equivalent effect to that of lansoprazole, clarithromycin and amoxicillin in terms of Helicobacter pylori eradication rates, improvements in gastroesophageal reflux and abdominal symptoms after treatment, although the eradication rate with a triple therapy including lafutidine is not influenced by genetic polymorphism of CYP2C19 activity [18,19] . Lafutidine is used as a preanesthetic medication to decrease gastric fluid acidity and volume [20,21] .…”